Geographical Variation in Medication Prescriptions : A Multiregional Drug-Utilization Study
Copyright © 2020 Russo, Orlando, Monetti, Galimberti, Casula, Olmastroni, Tragni and Menditto and EDU.RE.DRUG Group..
BACKGROUND: Studies have emphasized the importance of geographical factors and general practitioner (GP) characteristics in influencing drug prescriptions.
OBJECTIVES: To: (i) ascertain the prevalence rate (PR) of use of drugs in six therapeutic categories used for chronic conditions; (ii) assess how geographical characteristics and GP characteristics may influence drug prescribing.
METHODS: This study is part of the EDU.RE.DRUG Project, a national collaborative project founded by Italian Medicine Agency (AIFA). Cross-sectional analyses were undertaken employing the pharmacy-claim databases of four local health units (LHUs) located in two Italian regions: Lombardy and Campania. Six drug categories were evaluated: proton-pump inhibitors; antibiotics; respiratory-system drugs; statins; agents acting on the renin-angiotensin system; psychoanaleptic drugs. The PR was estimated according to drug categories at the LHU level. A linear multivariate regression analysis was undertaken to evaluate the association between the PR and geographical area, age and sex of GPs, number of patients, and percentage of patients aged >65 per GP.
RESULTS: LHUs in Campania showed a PR that was significantly higher than that in Lombardy. Antibiotics showed the highest PR in all the LHUs assessed, ranging from 32.5% in Lecco (Lombardy) to 59.7% in Naples-2 (Campania). Multivariate linear regression analysis confirmed the association of the PR with geographical area for all drug categories. Being located in Campania increased the possibility of receiving a drug prescription from the categories considered, with estimates more marked for antibiotics, proton-pump-inhibitors, and respiratory-system drugs.
CONCLUSIONS: This study provides information about the PR of medications used for treating common and costly conditions in Italy and highlighted a significant geographical variation. These insights could help to develop area-specific strategies to optimize prescribing behavior.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:11 |
|---|---|
| Enthalten in: |
Frontiers in pharmacology - 11(2020) vom: 07., Seite 418 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Russo, Veronica [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Drug use |
|---|
| Anmerkungen: |
Date Revised 15.04.2022 published: Electronic-eCollection Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.3389/fphar.2020.00418 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM311159761 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM311159761 | ||
| 003 | DE-627 | ||
| 005 | 20231225141648.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3389/fphar.2020.00418 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1037.xml |
| 035 | |a (DE-627)NLM311159761 | ||
| 035 | |a (NLM)32536861 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Russo, Veronica |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Geographical Variation in Medication Prescriptions |b A Multiregional Drug-Utilization Study |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 15.04.2022 | ||
| 500 | |a published: Electronic-eCollection | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a Copyright © 2020 Russo, Orlando, Monetti, Galimberti, Casula, Olmastroni, Tragni and Menditto and EDU.RE.DRUG Group. | ||
| 520 | |a BACKGROUND: Studies have emphasized the importance of geographical factors and general practitioner (GP) characteristics in influencing drug prescriptions | ||
| 520 | |a OBJECTIVES: To: (i) ascertain the prevalence rate (PR) of use of drugs in six therapeutic categories used for chronic conditions; (ii) assess how geographical characteristics and GP characteristics may influence drug prescribing | ||
| 520 | |a METHODS: This study is part of the EDU.RE.DRUG Project, a national collaborative project founded by Italian Medicine Agency (AIFA). Cross-sectional analyses were undertaken employing the pharmacy-claim databases of four local health units (LHUs) located in two Italian regions: Lombardy and Campania. Six drug categories were evaluated: proton-pump inhibitors; antibiotics; respiratory-system drugs; statins; agents acting on the renin-angiotensin system; psychoanaleptic drugs. The PR was estimated according to drug categories at the LHU level. A linear multivariate regression analysis was undertaken to evaluate the association between the PR and geographical area, age and sex of GPs, number of patients, and percentage of patients aged >65 per GP | ||
| 520 | |a RESULTS: LHUs in Campania showed a PR that was significantly higher than that in Lombardy. Antibiotics showed the highest PR in all the LHUs assessed, ranging from 32.5% in Lecco (Lombardy) to 59.7% in Naples-2 (Campania). Multivariate linear regression analysis confirmed the association of the PR with geographical area for all drug categories. Being located in Campania increased the possibility of receiving a drug prescription from the categories considered, with estimates more marked for antibiotics, proton-pump-inhibitors, and respiratory-system drugs | ||
| 520 | |a CONCLUSIONS: This study provides information about the PR of medications used for treating common and costly conditions in Italy and highlighted a significant geographical variation. These insights could help to develop area-specific strategies to optimize prescribing behavior | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a drug use | |
| 650 | 4 | |a drug-utilization | |
| 650 | 4 | |a general practitioner | |
| 650 | 4 | |a geographical difference | |
| 650 | 4 | |a pharmacy claims | |
| 650 | 4 | |a prevalence | |
| 700 | 1 | |a Orlando, Valentina |e verfasserin |4 aut | |
| 700 | 1 | |a Monetti, Valeria Marina |e verfasserin |4 aut | |
| 700 | 1 | |a Galimberti, Federica |e verfasserin |4 aut | |
| 700 | 1 | |a Casula, Manuela |e verfasserin |4 aut | |
| 700 | 1 | |a Olmastroni, Elena |e verfasserin |4 aut | |
| 700 | 1 | |a Tragni, Elena |e verfasserin |4 aut | |
| 700 | 1 | |a Menditto, Enrica |e verfasserin |4 aut | |
| 700 | 0 | |a EDU.RE.DRUG Group |e verfasserin |4 aut | |
| 700 | 1 | |a Catapanoa, Alberico L |e investigator |4 oth | |
| 700 | 1 | |a Tragni, Elena |e investigator |4 oth | |
| 700 | 1 | |a Menditto, Enrica |e investigator |4 oth | |
| 700 | 1 | |a Corrao, Giovanni |e investigator |4 oth | |
| 700 | 1 | |a Casula, Manuela |e investigator |4 oth | |
| 700 | 1 | |a Galimberti, Federica |e investigator |4 oth | |
| 700 | 1 | |a Olmastroni, Elena |e investigator |4 oth | |
| 700 | 1 | |a Russo, Veronica |e investigator |4 oth | |
| 700 | 1 | |a Orlando, Valentina |e investigator |4 oth | |
| 700 | 1 | |a Mucherino, Sara |e investigator |4 oth | |
| 700 | 1 | |a Scotti, Lorenza |e investigator |4 oth | |
| 700 | 1 | |a Zambon, Antonella |e investigator |4 oth | |
| 700 | 1 | |a Gambera, Marco |e investigator |4 oth | |
| 700 | 1 | |a Piccinelli, Rossana |e investigator |4 oth | |
| 700 | 1 | |a Sonzogni, Samanta |e investigator |4 oth | |
| 700 | 1 | |a Valsecchi, Valter |e investigator |4 oth | |
| 700 | 1 | |a Scopinaro, Eugenio |e investigator |4 oth | |
| 700 | 1 | |a Raineri, Sandro |e investigator |4 oth | |
| 700 | 1 | |a Speziali, Alessia |e investigator |4 oth | |
| 700 | 1 | |a Creazzola, Simona |e investigator |4 oth | |
| 700 | 1 | |a Tari, Michele |e investigator |4 oth | |
| 700 | 1 | |a Fusco, Mariano |e investigator |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |t Frontiers in pharmacology |d 2010 |g 11(2020) vom: 07., Seite 418 |w (DE-627)NLM208568891 |x 1663-9812 |7 nnns |
| 773 | 1 | 8 | |g volume:11 |g year:2020 |g day:07 |g pages:418 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3389/fphar.2020.00418 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 11 |j 2020 |b 07 |h 418 | ||